Abstract

Traditionally, the development of influenza products have focused on two axes: classic vaccines for disease prevention, and antiviral products for the treatment or prophylaxis of clinical influenza. In recent years, novel approaches have been under development for the prevention and treatment of influenza, and these include, for example, monoclonal antibodies (mAbs) that offer temporary protection via ‘passive immunisation’ or conjugate products that bind to the target on the influenza cell surface.

This article discusses the current challenges when developing new influenza compounds and potential regulatory avenues that could support novel therapies.